Rob Wright shares his thoughts on the 38^th Annual J.P. Morgan Healthcare Conference and “JPM” as we enter a decade that could be “roaring with cures.” Content specifically curated for professional development of c-level life science leaders.

Rob Wright provides a high-level overview of The Leadership Meeting, a pre-JPM conference with content specifically curated for professional development of c-level life science leaders.

Despite a banner year for Life Science Leader having diversity well represented on its covers, chief editor Rob Wright admits there is more work to be done and seeks help from readers in connecting to more diverse leaders of biopharma.

Jan G. J. van de Winkel, Ph.D., cofounder, president, and CEO since 2010, remembers when Genmab faced some pretty tough decisions.

Two Big Pharma executives explain how their organizations are investing for impact.

Ed Torres, managing partner at Lilly Ventures, shares how he and his wife got involved in making a difference for U.S. orphans.

Therapy designations and FDA approvals don’t mean much if the product can’t be manufactured at the level necessary to meet market demand. Here, a cross section of biopharma manufacturing executives offer their opinions on what to expect in biopharma manufacturing for 2020  and beyond.

As politics, finance and biopharma seem forever intertwined, we sought the counsel of five biopharmaceutical industry financial experts toward helping you prepare for what to expect in 2020 – and beyond.

Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.